Eli Lilly
Top Five Articles on 360Dx Last Week: NIH Funds Syphilis Dx; Sentencing in COVID Fraud Case; More
Last week, readers were most interested in a story about 10 new awards from NIH aimed at simplifying the testing process for congenital and adult syphilis.
FDA Approves Illumina Cancer Genomic Profiling Assay as CDx for Kinase Inhibitors From Bayer, Lilly
The test's first CDx approvals are for Bayer's Vitrakvi in solid tumors and for Lilly's Retevmo in non-small cell lung cancer.
Roche Licenses ALZpath's pTau217 Antibody for Use in Alzheimer's Blood Tests
pTau217, a blood-based biomarker highly predictive of beta-amyloid positivity, may eventually be used to identify patients eligible for new Alzheimer's drugs.
In Brief This Week: Roche; IVDR; Thermo Fisher Scientific; Centogene; ACCC; More
News items for the week of May 27, 2024.
Chugai Gains Japanese Approval for CDx for Eli Lilly's Retevmo
Roche's FoundationOne CDx cancer genomic profiling test was approved for the RET receptor tyrosine kinase inhibitor for RET fusion-positive solid tumors.